Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma
AUTHORS
Gordon, et al
Programs
OPN-2853
Download PDF
Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
AUTHORS
Mims, et al
Programs
OPN-2853
Download PDF
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
AUTHORS
Pemmaraju, et al
Programs
OPN-2853
Download PDF
Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors
AUTHORS
Patnaik, et al
Programs
OPN-2853
Download PDF
Resistance to BET inhibitors involves the Wnt/β-catenin Pathway in Uveal Melanoma
AUTHORS
Ambrosini, et al
Programs
OPN-51107
Download PDF
Response and Resistance to Bromodomain Inhibition in Acute Myeloid Leukemia
AUTHORS
Huang, et al
Programs
OPN-51107
Download PDF
Broad Anti-Tumor Activity of a Novel BET Bromodomain Inhibitor
AUTHORS
Ma, et al
Programs
OPN-51107
Download PDF
Efficacy and Mechanismof Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies
AUTHORS
Mead, et al
Programs
OPN-51107
Download PDF